Advertisement
Advertisement
U.S. Markets open in 35 mins
Advertisement
Advertisement
Advertisement
Advertisement

Janux Therapeutics, Inc. (JANX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.35-0.38 (-3.54%)
At close: 04:00PM EDT
10.35 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.73
Open10.97
Bid4.10 x 800
Ask16.36 x 900
Day's Range9.82 - 11.30
52 Week Range9.39 - 37.99
Volume130,143
Avg. Volume82,581
Market Cap430.679M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

    SAN DIEGO, May 10, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

  • Business Wire

    Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

    SAN DIEGO, April 26, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced its upcoming presentation of preclinical data for the Company’s two lead TRACTr programs, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008), in separate poster presentations at the 18th A

  • Business Wire

    Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

    SAN DIEGO, March 18, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

Advertisement
Advertisement